+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Acne

  • ID: 4533470
  • Report
  • March 2021
  • Region: Global
  • 46 pages
  • Datamonitor Healthcare
This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The publisher estimates that in 2019, there were approximately 612.5 million prevalent cases of acne worldwide, and forecasts that number to increase to 658.6 million prevalent cases by 2028.
  • Approved drugs in the acne space focus on a wide variety of targets. These drugs are administered via the oral and topical routes.
  • The majority of industry-sponsored drugs in active clinical development for acne are in Phase II, with just a single product in the NDA/BLA stage.
  • Therapies in development for acne focus on a wide variety of targets. The majority of the pipeline drugs are administered via the topical route, with the remainder being oral, subcutaneous, intranasal, or intravenous formulations.
  • The only high-impact upcoming event for drugs in the acne space is an expected PDUFA date for Twyneo. The overall likelihood of approval of a Phase I dermatology-general asset is 20.2%, and the average probability a drug advances from Phase III is 68%. Drugs, on average, take 8.8 years from Phase I to approval in the dermatology-general space, as well as in the overall dermatology space.
  • The distribution of clinical trials across Phase I–IV indicates that the majority of trials for acne have been in the late phases of development, with 52% of trials in Phase III–IV, and 48% in Phase I–II.
  • The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the acne space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for acne, with 35 trials.
  • GlaxoSmithKline leads industry sponsors with by far the highest overall number of clinical trials for acne, followed by AbbVie.
Note: Product cover images may vary from those shown
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
  • Topical therapy
  • Systemic therapy
  • Physical treatments
EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • VB 1953 for Acne (June 16, 2020)
  • DMT310 for Acne (June 10, 2020)
  • FCD105 for Acne (June 2, 2020)
  • Twyneo for Acne (December 30, 2019)
KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • Cassiopea’s Winlevi Brings New Drug Class To Acne Market
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • GSK Inks Dermatology Pact With Eligo
  • L’Oreal’s Microbiome Explorations Lead To Micreos Deal For Next-Gen Antibacterial
  • Paratek, Almirall Partner To Bring Acne Medicine To China
REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
BIBLIOGRAPHY
  • Prescription information
APPENDIX

LIST OF FIGURES
Figure 1: Trends in prevalent cases of acne, 2019–28
Figure 2: Overview of pipeline drugs for acne in the US
Figure 3: Pipeline drugs for acne, by company
Figure 4: Pipeline drugs for acne, by drug type
Figure 5: Pipeline drugs for acne, by classification
Figure 6: VB 1953 for Acne (June 16, 2020): Phase II - Facial Acne Vulgaris
Figure 7: DMT310 for Acne (June 10, 2020): Phase IIb - 003
Figure 8: FCD105 for Acne (June 2, 2020): Phase II - Acne Vulgaris
Figure 9: Twyneo for Acne (December 30, 2019): Phase III - SGT-65-04, Phase III - SGT-65-05
Figure 10: Key upcoming events in acne
Figure 11: Probability of success in the dermatology-general pipeline
Figure 12: Clinical trials in acne
Figure 13: Top 10 drugs for clinical trials in acne
Figure 14: Top 10 companies for clinical trials in acne
Figure 15: Trial locations in acne
Figure 16: Acne trials status
Figure 17: Acne trials sponsors, by phase

LIST OF TABLES
Table 1: Prevalent cases of acne, 2019–28
Table 2: Marketed drugs for acne
Table 3: Pipeline drugs for acne in the US
Table 4: VB 1953 for Acne (June 16, 2020)
Table 5: DMT310 for Acne (June 10, 2020)
Table 6: FCD105 for Acne (June 2, 2020)
Table 7: Twyneo for Acne (December 30, 2019)
Table 8: Historical global sales, by drug ($m), 2015–19
Table 9: Forecasted global sales, by drug ($m), 2021–25
Note: Product cover images may vary from those shown
Adroll
adroll